Articles tagged with Heart Failure
A new study found that black patients have higher concentrations of activated fatty acids after a heart attack than white patients, indicating potential targets for personalized diagnosis and treatment of heart failure. Researchers discovered distinct lipid biomarkers may offer new approaches to delay or prevent cardiac failure.
Two new AHA statements emphasize the impact of social determinants on heart failure outcomes and caregiver demands. The statements advocate for an interprofessional healthcare team to address non-medical barriers, while also identifying challenges faced by unpaid family caregivers who serve as primary support.
Researchers found a significant increase in premature coronary artery disease deaths among rural women under 65, while also noting that people living in rural areas have lower survival rates for heart failure. This disparity highlights the need for targeted public health efforts to improve cardiovascular health in rural communities.
A University of South Florida-led mouse cardiac healing study reveals faster heart repair and improved survival in female mice compared to males after a heart attack. The research suggests that sex-specific therapies may be more effective in managing heart failure, with potential applications for delayed or prevented cardiac inflammation.
Research from Joslin Diabetes Center found that autoantibodies against heart muscle proteins are associated with increased volume of the left ventricle, reduced pumping function, and higher risk of failure. The study suggests a novel process involving the heart linked to poor glycemic control in type 1 diabetes patients.
A new study found vericiguat significantly lowers cardiovascular death and hospitalization rates in patients with worsening heart failure. With a median follow-up period of 10.8 months, the drug showed a 10% lower rate of primary endpoint events compared to placebo.
A new study suggests that local doctors in rural areas can safely and effectively care for patients with left ventricular assist devices, reducing travel burdens and improving survival rates. Shared medical care eliminates the need for extensive travel, eases financial and emotional strains on patients.
Vericiguat, a novel guanylate cyclase stimulator agent, has shown significant benefits in reducing negative health events in patients with worsening chronic heart failure. The VICTORIA trial demonstrated an absolute reduction of 4.2% in patients already receiving optimal care.
A recent study published in JAMA Network reveals that COVID-19 can cause acute myocardial inflammation leading to fatigue and signs of heart failure. Researchers identified the presentation of this condition in a patient who recovered from influenzalike syndrome and developed symptoms a week after upper respiratory tract symptoms.
New research suggests that statin therapy may protect against heart damage caused by certain breast cancer therapies. A population-based study found a significantly lower risk of treatment-related heart failure among women taking statins while receiving anthracyclines or trastuzumab.
A recent investigation found that approximately one-third of people with heart failure are not being screened for iron deficiency, leading to avoidable hospital stays and increased costs. The study estimates that this undermanagement results in an additional £21.5 million per year spent on managing co-morbid patients.
A study of over 99,000 postmenopausal women found that consuming 58-74 grams of protein per day significantly reduced the risk of developing atrial fibrillation. Increasing protein intake by 10-20 grams daily can potentially lower this risk and has implications for cardiovascular health.
A new study suggests that giving birth to a low-weight baby under 5.5 pounds may be an independent risk factor for developing changes in heart function that can lead to heart failure. Researchers found that women who experienced adverse pregnancy outcomes, such as preeclampsia or pre-term birth, had a higher risk of heart failure at 30...
Researchers at Boston Children's Hospital have successfully used gene therapy to reverse cardiac dysfunction and scarring in two mouse models of Barth syndrome. The treatment, which replaced the mutated TAZ gene, prevented progressive cardiomyopathy and restored heart function in both whole-body and heart-only TAZ deletion mice.
Researchers found that liver fibrosis is tied to a specific type of heart failure, known as preserved ejection fraction heart failure (HFpEF), which affects people with and without HIV and hepatitis C. The study suggests that preventing liver fibrosis may be crucial in reducing the risk of HFpEF.
A new study by Mayo Clinic researchers found that catheter ablation reduced the risk of death or hospitalization due to worsening heart failure in patients with both conditions. The study analyzed data from over 289,000 patients and showed an 18% reduction in risk for those who received ablation.
The DIASyM research cluster will use state-of-the-art mass spectrometry to analyze blood parameters of patients with heart failure and compare them to healthy individuals. This will help identify biomarkers and understand the interactions between biological processes, leading to new approaches for diagnosis, therapy, and prevention.
A new wearable sensor and AI technology combo can predict worsening heart failure in patients up to 80% of the time, allowing for early intervention and potential prevention of rehospitalizations. The system has shown promising results in detecting changes in heart rate, rhythm, and other normal activities before a hospitalization occurs.
Researchers developed a non-invasive sensor patch that accurately predicted worsening heart failure and hospitalization among veterans with heart failure. The technology successfully detected worsening heart failure up to 6.5 days before hospital readmission, with an accuracy rate of over 80%.
A large meta-analysis of SGLT2 inhibitor trials found consistent cardiovascular benefits in diverse subsets of patients with type 2 diabetes, including those without established cardiovascular disease. The study showed a significant reduction in major adverse cardiac events, cardiovascular deaths, and hospitalizations for heart failure.
A University of Tsukuba study reveals that histamine, a key factor in inflammation, can control the severity of cardiorenal syndrome in mice. Histamine agonist drug prevents further damage in a mouse model of cardiorenal dysfunction, showing protective changes in gene expression.
A microsimulation study found that nurse home visits improved health outcomes and reduced readmissions for patients with heart failure, while also being more effective than standard care. The intervention increased quality-adjusted life years (QALYs) and costs, resulting in an ICER of $19,570 per QALY gained.
Researchers have identified a link between abnormal calcium release and arrhythmias in heart failure, suggesting new therapies may improve early Ca2+ release. Restoration of AP phase 1 repolarization could mitigate defective excitation-contraction coupling and reduce sudden death risk.
A new analysis of patients on heart pumps found that the newer generation device provides better treatment outcomes regardless of initial therapy goals. The study suggests that categorizing patients into distinct groups may not be necessary, and a single treatment goal of extending survival and improving quality of life could suffice.
Researchers at UT Southwestern Medical Center found a significant association between malignant left ventricular hypertrophy and an increased risk of heart failure among black individuals. The study, published in the journal Circulation, suggests that early intervention can be beneficial in preventing future risk.
A new study found that cardiovascular diseases, including heart failure, atrial fibrillation, and coronary heart disease, are each linked with a higher risk of developing kidney failure. Adults hospitalized with heart failure had an 11.4-times higher risk of developing kidney failure than individuals without cardiovascular disease.
A UCLA-led study identified neuropeptide Y as a clear predictor of death in patients with stable heart failure. Patients with higher levels are 10 times more likely to die within one to three years.
A population study found that diabetes is an independent risk factor for heart failure, with 21% of diabetic patients developing heart failure over a 10-year period. This study supports the concept of diabetic cardiomyopathy and highlights the need for further research into this association.
Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who receive anthracycline chemotherapy are at higher risk of developing heart failure within one year. Researchers developed a risk score system to identify high-risk patients and tailor treatment plans accordingly.
A new study has identified a genetic variation that significantly increases the risk of heart failure in African and Latino Americans. The transthyretin or TTR V122I genetic variant was associated with an increased risk of heart failure, with patients being two-fold more likely to have the condition.
A genetic variant found in 3% of individuals of African ancestry is a significant cause of heart failure, but it's significantly underdiagnosed. The FDA has approved a therapy for this condition, allowing for earlier diagnosis and treatment.
Researchers found that beta-blockers increase the risk of hospitalizations for heart failure among patients with 'stiff heart' heart failure, characterized by a normal squeeze but impaired relaxation of the heart muscle. Beta-blocker use was associated with a 74% higher risk of hospitalizations in this patient population.
A nationwide cohort study in Korea found that frequent tooth brushing reduced the risk of atrial fibrillation and heart failure by 10% and 12%, respectively. The study suggests a potential mechanism: reducing bacteria in the subgingival biofilm, which can prevent translocation to the bloodstream.
A new Yale study found a clear association between neurohormonal blockade therapy and increased survival and quality of life for patients with left ventricular assist devices. The study, which analyzed over 12,000 patients, showed a 56% survival rate for those taking NHB therapy compared to 43.9% for those not on the medications.
Researchers developed an AI algorithm based on electronic health records data that accurately predicted life expectancy for heart failure patients, achieving an 88% success rate. The model identified eight readily available variables to determine low- and high-risk of death, providing valuable insight for informed medical decisions.
Researchers developed a novel bionic pacemaker that reads breathing signals to speed up and slow down the heart. This approach increases heart efficiency by 20% within two weeks, offering new hope for heart failure treatment.
Researchers found that patients who stopped using meth experienced a 43% improvement in their heart's pumping ability, while those who continued to use the drug saw a 4% worsening. These findings suggest that addressing meth abuse can lead to significant improvements in heart failure treatment.
Several high-impact clinical trials have yielded promising results, including the ATHENA trial showing azathioprine to be as effective as mycophenolate mofetil in preventing chronic kidney rejection, and the NOBILITY trial demonstrating that obinutuzumab improves kidney health in patients with lupus nephritis. Additionally, a phase 3 s...
Patients who underwent metabolic surgery had a lower risk of developing systolic heart failure and dying from recurrent myocardial infarction compared to those without surgery. The study found significant cardiovascular benefits of metabolic surgery, emphasizing its potential as part of the treatment plan for patients with severe obesi...
Researchers have identified HIPK2 as a novel regulator of heart failure progression. The kinase was found to play a critical role in maintaining cardiac function, with its deletion leading to progressive deterioration and apoptosis in heart muscle cells.
Kaiser Permanente research identifies a national trend of increasing deaths due to heart failure among US seniors, with over 647,000 people dying from heart disease in 2017. The study highlights the importance of addressing heart health in older adults as the population continues to age and grow.
Patients who self-identified as black, Latinx, female or over the age of 75 were less likely to be admitted to cardiology service despite heart failure diagnosis. The study highlights racial inequities in access to specialized care, which may contribute to disparities in readmissions and outcomes.
A study published in the Journal of Applied Physiology found that exercise can reduce artery stiffness associated with heart failure. Regardless of intensity level or duration, any type of physical activity was beneficial for heart health compared to no exercise at all.
Researchers at the University of Arizona have shown that Aliskiren, a FDA-approved drug, can delay the progression of congestive heart failure and lengthen survival rates in properly identified patients. The study used non-invasive technology to evaluate changes in muscle mass and fluid retention over time.
Researchers found that overweight individuals had the lowest mortality risk among those with established heart failure, contrary to previous expectations. The 'obesity paradox' suggests that obese patients may tolerate disease-modifying and prognostic medications better than non-obese patients.
Researchers at Queen Mary University of London used AI to analyze 17,000 healthy UK Biobank volunteers' heart MRI images, finding genetic factors account for 22-39% variation in left ventricle size and function. The study identified 14 genome regions associated with heart structure and function.
A new study published in The Journal of Thoracic and Cardiovascular Surgery found that hearts from donors with acute stress-induced cardiomyopathy can be safely transplanted without affecting recipient outcomes. This breakthrough could lead to a significant increase in the supply of donor hearts, estimated at 20-30%.
A study found that Asian patients with low body mass index (BMI) and high waist-to-height ratio (WHtR) have worse heart failure outcomes. The 'lean-fat' subgroup had the highest risk of composite events and worst quality-of-life scores.
Researchers have successfully recorded and processed data from 43 patients with heart failure using a machine learning-based ballistocardiogram (BCG) scale. The device measures circulation pulsing to detect worsening heart failure symptoms, potentially sparing patients hospital stays.
Research suggests dapagliflozin can reduce death and hospitalization rates in patients with heart failure, as well as improve health-related quality of life. The study found a 26% reduced risk of primary outcome in the dapagliflozin group compared to placebo, with benefits seen in both patients with and without type 2 diabetes.
A new study developed a machine-learning derived model that can predict future heart failure among patients with diabetes. The WATCH-DM risk score is based on 10 variables, including weight, age, and diabetes control, and identifies patients at high risk of heart failure.
Researchers at CNIC discover strategies to inhibit kinase GSK3? in mice with ARVC5, reducing fibrosis and improving heart function. The study aims to translate the results to patients and investigate gene therapy strategies for potential cure.
A new study suggests that heart failure care must address patients' broader health to improve survival rates. The research found that while the risk of death from cardiovascular causes declined, non-cardiovascular deaths increased, highlighting the need for a more holistic approach.
Researchers are conducting a national trial to identify transthyretin cardiac amyloidosis (ATTR-CM) in older minority patients with congestive heart failure. The goal is to use highly sensitive heart imaging and blood tests to diagnose the disease earlier, potentially leading to better patient outcomes.
Patients with diabetes are at greater risk of developing heart failure after a heart attack, with a 56% higher risk compared to those without diabetes. The study also found that diabetic patients who develop heart failure have a much higher risk of dying in the following years.
A small study found a 30% increased likelihood of developing heart failure in patients with malaria infection. The researchers identified 3,989 malaria cases and followed up with the patients for 11 years, revealing 69 cases of heart failure.
A new study from the European Society of Cardiology reveals that heart failure patients have a high likelihood of developing dementia-type brain lesions, similar to those found in stroke patients. The study also suggests a link between heart failure and an increased risk for dementia.
Treatment with sacubitril/valsartan significantly improves cardiac structure and function in patients with reduced ejection fraction heart failure. The drug's neprilysin inhibition also reduces blood levels of biomarker NT-proBNP, associated with lower risk of death and hospitalization.
The PARAGON-HF trial found that sacubitril-valsartan reduced hospitalizations for heart failure in lower ejection fraction patients, but not overall; women and those with ejection fractions 45-57% showed benefits.
Procizumab shows high therapeutic potential in treating acute heart failure and cardiogenic shock by targeting the DPP3 enzyme. The company is setting up GMP process for Procizumab manufacturing and expects to enter regulatory non-clinical safety studies next year.